These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12623912)

  • 1. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.
    Gami AS; Montori VM; Erwin PJ; Khan MA; Smith SA;
    BMJ; 2003 Mar; 326(7388):528-9. PubMed ID: 12623912
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
    Costa J; Borges M; David C; Vaz Carneiro A
    BMJ; 2006 May; 332(7550):1115-24. PubMed ID: 16585050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and lipids - a conundrum.
    Valabhji J; Robinson S
    Diabet Med; 2001 Mar; 18(3):250. PubMed ID: 11318849
    [No Abstract]   [Full Text] [Related]  

  • 4. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
    Haffner SM
    Diabetes Care; 1997 Apr; 20(4):469-71. PubMed ID: 9096961
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?
    Rowland Yeo K; Yeo WW
    Heart; 2002 May; 87(5):423-7. PubMed ID: 11997409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing lipid disorders: further evaluation of the VA-HIT.
    Vajo Z; Reaven PD;
    Curr Diab Rep; 2003 Jun; 3(3):245-7. PubMed ID: 12762973
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipid modification and coronary heart disease in type 2 diabetes: different from the general population?
    Feher MD; Elkeles RS
    Heart; 1999 Jan; 81(1):10-1. PubMed ID: 10220537
    [No Abstract]   [Full Text] [Related]  

  • 9. Coronary artery disease and diabetes.
    Rutter MK; Marshall SM; McComb JM
    Heart; 1997 Dec; 78(6):527-8. PubMed ID: 9470860
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of dyslipidemia in adults with diabetes. American Diabetes Association.
    Diabetes Care; 1998 Jan; 21(1):179-82. PubMed ID: 9538989
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins.
    Pearson TA
    Am J Cardiol; 1998 Nov; 82(10A):28S-30S. PubMed ID: 9860353
    [No Abstract]   [Full Text] [Related]  

  • 12. [Screening and management of coronary artery disease in diabetic patients].
    Kraiem S; Abassi C; Annabi N; Smaali I; Issaa I; Wali M; Malou M; Hannachi S; Longo S; Battikh K; Slimane ML
    Tunis Med; 2006 Oct; 84(10):670-6. PubMed ID: 17193866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes: preventing coronary heart disease in a high risk group.
    Feher MD
    Heart; 2004 Jun; 90 Suppl 4(Suppl 4):iv18-21. PubMed ID: 15145907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of lipid-lowering therapy.
    Stein JH; McBride P
    J Am Board Fam Pract; 1998; 11(5):423-4. PubMed ID: 9796776
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials.
    Pignone M; Phillips C; Mulrow C
    BMJ; 2000 Oct; 321(7267):983-6. PubMed ID: 11039962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
    Vakkilainen J; Steiner G; Ansquer JC; Perttunen-Nio H; Taskinen MR
    Diabetes Care; 2002 Mar; 25(3):627-8. PubMed ID: 11874962
    [No Abstract]   [Full Text] [Related]  

  • 18. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
    Green L
    Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. After the meta-analyses: a commentary on treatment of dyslipidaemia in the primary prevention of coronary heart disease.
    Silberberg JS
    Aust N Z J Med; 1994 Dec; 24(6):717-21. PubMed ID: 7717926
    [No Abstract]   [Full Text] [Related]  

  • 20. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
    Oparil S
    Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.